New generation vaccines /

New generation vaccines /

Saved in:
Bibliographic Details
Edition:2nd ed., rev. and expanded.
Imprint:New York : M. Dekker, 1997.
Description:xvi, 1214 p. : ill. ; 29 cm.
Language:English
Subject:
Vaccines.
Vaccines.
Vaccines.
Format: E-Resource Print Book
URL for this record:http://pi.lib.uchicago.edu/1001/cat/bib/2902982
Hidden Bibliographic Details
Other authors / contributors:Levine, Myron M. (Myron Max), 1944-
ISBN:0824700619 (hardcover : alk. paper)
Notes:Includes bibliographical references and index.

MARC

LEADER 00000pam a2200000 a 4500
001 2902982
003 ICU
005 20030525201700.0
008 970328s1997 nyua b 001 0 eng c
010 |a  97012541  
020 |a 0824700619 (hardcover : alk. paper) 
035 |a (NhCcYBP)YBT 97012541 
035 |a (NhCcYBP)YBP97206115515 
040 |a DNLM/DLC  |c DLC  |d DLC  |d OrLoB-B  |d OCoLC 
050 0 0 |a QR189  |b .N489 1997 
060 1 0 |a QW 805 N5316 1997 
082 0 0 |a 615/.372  |2 21 
245 0 0 |a New generation vaccines /  |c edited by Myron M. Levine ... [et al.]. 
250 |a 2nd ed., rev. and expanded. 
260 |a New York :  |b M. Dekker,  |c 1997. 
300 |a xvi, 1214 p. :  |b ill. ;  |c 29 cm. 
336 |a text  |b txt  |2 rdacontent  |0 http://id.loc.gov/vocabulary/contentTypes/txt 
337 |a unmediated  |b n  |2 rdamedia  |0 http://id.loc.gov/vocabulary/mediaTypes/n 
338 |a volume  |b nc  |2 rdacarrier  |0 http://id.loc.gov/vocabulary/carriers/nc 
504 |a Includes bibliographical references and index. 
505 0 0 |g 1.  |t Vaccines and Vaccination in Historical Perspective /  |r Myron M. Levine and Rosanna Lagos --  |g 2.  |t The Traditional Vaccines: An Overview /  |r Gordon L. Ada --  |g 3.  |t An Overview of Biotechnology as Applied to Vaccine Development /  |r Graeme C. Woodrow --  |g 4.  |t Initial Clinical Evaluation of New Vaccine Candidates: Phase 1 and 2 Clinical Trials of Safety, Immunogenicity, and Preliminary Efficacy /  |r Carol O. Tacket, Tacket J. Mattheis and Margaret Baker Rennels --  |g 5.  |t Long-Term Evaluation of Vaccine Protection: Methodological Issues for Phase 3 Trials and Phase 4 Studies /  |r John D. Clemens, Abdollah Naficy and Malla R. Rao --  |g 6.  |t Economic Analyses of Vaccines and Vaccination Programs: Evaluating the Economic Rationale for Immunization /  |r Orin S. Levine and Benjamin Schwartz --  |g 7.  |t Reaping the Benefits: Getting Vaccines to Those Who Need Them /  |r J. W. Lee, Bruce Aylward and Harry F. Hull [et al.] --  |g 8.  |t Progress and Challenges in Modern Vaccinology: An Immunologist's Perspective /  |r Gustav J. V. Nossal --  |g 9.  |t The Eradication of Vaccine-Preventable Diseases /  |r William Foege --  |g 10.  |t Recent Advances in Immunology: Impact on Vaccine Development /  |r Marcelo B. Sztein and Graham F. Mitchell --  |g 11.  |t Computer Prediction of T-Cell Epitopes /  |r Anne S. De Groot, Gabriel E. Meister and James L. Cornette [et al.] --  |g 12.  |t Identification of B- and T-Cell Epitopes Through Structural Characterization and Peptide Technology /  |r Juan A. Cooper and Allan J. Saul --  |g 13.  |t The Gastrointestinal Mucosal Immune System /  |r Stephen P. James --  |g 14.  |t Adjuvants for the Future /  |r Robert Edelman --  |g 15.  |t Proteosomes for Improved Nasal, Oral, or Injectable Vaccines /  |r George H. Lowell --  |g 16.  |t Liposomes as Adjuvants for Vaccines /  |r Carl R. Alving --  |g 17.  |t Prospects for the Development of New and Improved Vaccines Through the Use of Microencapsulation Technology /  |r Derek T. O'Hagan --  |g 18.  |t Antigen Cochleate Preparations for Oral and Systemic Vaccination /  |r Raphael J. Mannino and Susan Gould-Fogerite --  |g 19.  |t Ty Virus-like Particles as an Antigen Delivery System /  |r Guy T. Layton --  |g 20.  |t Immunopotentiating Reconstituted Influenza Virosomal Vaccine Delivery System /  |r Reinhard Gluck and Stanley J. Cryz, Jr. --  |g 21.  |t Mutant Pertussis and Escherichia coli Heat-Liable Toxins as Adjuvants for Enhancing Local and Systemic Immune Responses to Coadministered, Nonliving Antigens /  |r Gillian Douce, Gordon Dougan and MariaGrazia Pizza [et al.] --  |g 22.  |t Oral Vaccine Production in the Edible Tissues of Transgenic Plants /  |r Charles J. Arntzen and Hugh S. Mason --  |g 23.  |t DNA-Based Vaccines: Extending the Technology /  |r Stephen Albert Johnston, Kathryn F. Sykes and Michael A. Barry --  |g 24.  |t Vaccination Against Influenza with Plasmid DNA: Cross-Strain and Homologous Protection /  |r John J. Donnelly, Jeffrey B. Ulmer and Margaret A. Liu --  |g 25.  |t Vaccinia Virus as a Live Vector for Expression of Immunogens /  |r Charles Flexner and Bernard Moss --  |g 26.  |t Attenuated Poliovirus as Live Vector /  |r Matthias Gromeier, Hui-Hua Lu and Steffen Mueller [et al.] --  |g 27.  |t Attenuated Salmonella as a Live Vector for Expression of Foreign Antigens.  |g i.  |t Expressing Bacterial Antigens /  |r S. N. Chatfield and Gordon Dougan.  |g ii.  |t Carrying Viral Antigens /  |r Fiorian Schodel.  |g iii.  |t Salmonella Expressing Protozoal Antigens /  |r Myron M. Levine, James E. Galen and Marcelo B. Sztein [et al.] --  |g 28.  |t BCG as a Recombinant Vaccine Vector /  |r Glenn J. Fennelly, William R. Jacobs, Jr. and Barry R. Bloom --  |g 29.  |t Attenuated Vibrio cholerae as a Live Vector for Expression of Foreign Antigens /  |r Joan R. Butterton and Stephen B. Calderwood --  |g 30.  |t New and Improved Vaccines Against Pertussis /  |r Erik L. Hewlett and James D. Cherry --  |g 31.  |t New and Improved Vaccines Against Diphtheria and Tetanus /  |r Rino Rappuoli --  |g 32.  |t Progress in Development of New Attenuated Strains of Salmonella typhi as Live Oral Vaccines Against Typhoid Fever /  |r Myron M. Levine, Carol O. Tacket and James E. Galen [et al.] --  |g 33.  |t New and Improved Vaccines Against Cholera.  |g i.  |t Attenuated Vibrio cholerae O1 and O139 Strains as Live Oral Cholera Vaccines /  |r James B. Kaper, Carol O. Tacket and Myron M. Levine.  |g ii.  |t Oral B Subunit Killed Whole-Cell Cholera Vaccine /  |r Jan Holmgren, Marianne Jertborn and Ann-Mari L. Svennerholm --  |g 34.  |t New and Improved Vaccines Against Meningococcal Disease /  |r Wendell D. Zollinger --  |g 35.  |t Epidemiological Impact of Conjugate Vaccines on Invasive Disease Caused by Haemophilus influenzae Type b /  |r Jay D. Wenger, Robert Booy and Paul T. Heath [et al.] --  |g 36.  |t Conjugate Vaccines Against Streptococcus pneumoniae /  |r David L. Klein and Ronald W. Ellis --  |g 37.  |t Vaccine Development for Rickettsial Infections: Rocky Mountain Spotted Fever, Epidemic Typhus, and Scrub Typhus /  |r Kimberly W. Schuenke and David H. Walker --  |g 38.  |t New and Improved Vaccines Against Influenza /  |r Mary Lou Clements and Ina Stephens --  |g 39.  |t New Vaccines Against Hepatitis A /  |r Jack T. Stapleton and Stanley M. Lemon --  |g 40.  |t New and Improved Vaccines for Dengue, Japanese Encephalitis, and Yellow Fever Viruses /  |r Niranjan Kanesa-thasan, Robert Putnak and Charles H. Hoke, Jr. --  |g 41.  |t Improved Vaccines Against Rabies /  |r Zhen Fang Fu, Bernhard Dietzschold and Stanley A. Plotkin [et al.] --  |g 42.  |t Combination Vaccines for Routine Infant Immunization: Prospects, Progress, and Dilemmas /  |r Carole Heilman and N. Regina Rabinovich --  |g 43.  |t New Vaccines Against Tuberculosis /  |r Douglas Young and Uli Fruth --  |g 44.  |t Live Attenuated Varicella Vaccines /  |r Michiaki Takahashi and Anne A. Gershon --  |g 45.  |t Vaccines Against Rotavirus /  |r Paul A. Offit, H. Fred Clark and Albert Z. Kapikian --  |g 46.  |t Experimental HIV-1 Vaccines /  |r Mary Lou Clements --  |g 47.  |t Vaccines Against Respiratory Syncytial Virus and Parainfluenza Virus Type 3 /  |r James E. Crowe, Jr., Peter L. Collins and Robert M. Chanock [et al.] --  |g 48.  |t Herpes Simplex Vaccines /  |r Richard J. Whitley --  |g 49.  |t Vaccines Against Arenaviruses and Filoviruses /  |r J. Christopher S. Clegg and Anthony Sanchez --  |g 50.  |t Vaccines Against Papillomavirus Infections /  |r Robert W. Tindle and Ian H. Frazer --  |g 51.  |t Vaccines Against Streptococcus pyogenes Infections /  |r Debra E. Bessen and Vincent A. Fischetti --  |g 52.  |t O-Specific Polysaccharide-Protein Conjugates for Prevention of Enteric Bacterial Diseases /  |r John B. Robbins, Rachel Schneerson and Shousun C. Szu --  |g 53.  |t Vaccines Against Gonococcal Infection /  |r Timothy A. Mietzner and Myron S. Cohen --  |g 54.  |t Vaccines Against Shigella Infections.  |g i.  |t Escherichia coli- or Salmonella typhi-Expressing Shigella Antigens /  |r Thomas Larry Hale and Malabi M. Venkatesan.  |g ii.  |t Engineered Attenuated Mutants of Shigella as Live Oral Vaccines /  |r Fernando Noriega, Samuel B. Formal and Karen L. Kotloff [et al.] --  |g 55.  |t Vaccines Against Enterotoxigenic Escherichia coli Infections.  |g i.  |t Oral Inactivated Vaccines Against Enterotoxigenic Escherichia coli /  |r Ann-Mari L. Svennerholm, Christina Ahren and Marianne Jertborn.  |g ii.  |t Live Oral Vaccines and Subunit (Purified Fimbriae and Toxin Subunit) Vaccines /  |r Carol O. Tacket and Myron M. Levine --  |g 56.  |t Vaccines Against Campylobacter jejuni /  |r Daniel A. Scott, Shahida Baqar and Donald H. Burr [et al.] --  |g 57.  |t Vaccines Against Lyme Disease /  |r Robert Edelman --  |g 58.  |t Vaccines Against Dental Caries Infection /  |r Daniel J. Smith and Martin A. Taubman --  |g 59.  |t Vaccines Against Klebsiella, Pseudomonas, and Septicemic E. coli Infections /  |r Alan S. Cross and Stanley J. Cryz, Jr. --  |g 60.  |t Vaccines Against Escherichia coli and Proteus Urinary Tract Infections /  |r Harry L. T. Mobley --  |g 61.  |t Vaccines Against Helicobacter pylori /  |r Adrian Lee and Christopher Doidge --  |g 62.  |t Vaccines for Staphylococcus aureus Infections /  |r Ali I. Fattom and Robert B. Naso --  |g 63.  |t Vaccines Against Malaria.  |g i.  |t Synthetic Peptide Vaccines Against the Sporozoite Stage of Plasmodium /  |r Elizabeth H. Nardin and Ruth S. Nussenzweig.  |g ii.  |t Vaccines Designed to Induced Protective T-Cell Reponses Against Plasmodium-Infected Hepatocytes /  |r John B. Sacci, Jr., Eileen D. Franke and Stephen L. Hoffman.  |g iii.  |t Spf66 Vaccine Against Asexual Erythrocytic Stages of P. falciparum /  |r Roberto Amador and Manuel E. Patarroyo. 
505 8 0 |g iv.  |t Vaccines Against Asexual Blood Stages of Plasmodium falciparum /  |r Robin F. Anders.  |g v.  |t Vaccines Against Sexual-Stage Parasites of P. falciparum: Transmission-Blocking Vaccines /  |r David C. Kaslow --  |g 64.  |t Vaccines Against Leishmaniasis /  |r Carol L. Eisenberger and Charles L. Jaffe --  |g 65.  |t Vaccines Against Schistosomiasis /  |r Gilles J. Riveau and Andre Capron --  |g 66.  |t Antitumor Vaccines /  |r Karl Erik Hellstrom, Ingegerd Hellstrom and Lieping Chen --  |g 67.  |t Vaccine Therapy /  |r Donald S. Burke --  |g 68.  |t Vaccines to Prevent Pregnancy /  |r Vernon C. Stevens and Warren R. Jones --  |g 69.  |t An Anti-arthropod Vaccine: TickGARD - A Vaccine to Prevent Cattle Tick Infestations /  |r Gary S. Cobon --  |g 70.  |t Large-Scale Production of Live Attenuated Bacterial and Viral Vaccines /  |r Stanley J. Cryz, Jr. and Reinhard Gluck --  |g 71.  |t Vaccine Development: The Long Road from Initial Idea to Product Licensure /  |r Jens-Peter Gregersen --  |g 72.  |t Inadvertant Nontarget Effects of Live Vaccines /  |r Myron M. Levine and Eileen M. Barry --  |g 73.  |t The Role of the Food and Drug Administration in Vaccine Testing and Licensure /  |r Bascomb F. Anthony and Ann Sutton. 
650 0 |a Vaccines.  |0 http://id.loc.gov/authorities/subjects/sh85141718 
650 1 2 |a Vaccines. 
650 7 |a Vaccines.  |2 fast  |0 http://id.worldcat.org/fast/fst01163573 
700 1 |a Levine, Myron M.  |q (Myron Max),  |d 1944-  |0 http://id.loc.gov/authorities/names/n90657798  |1 http://viaf.org/viaf/37071439 
901 |a ToCBNA 
903 |a HeVa 
035 |a (OCoLC)36682381 
929 |a cat 
999 f f |i 5ff11a45-0213-513c-af68-efb93787e783  |s e3b508a8-5a23-5604-8259-52ad4654e415 
928 |t Library of Congress classification  |a QR189 .N489 1997  |l JCL  |c JCL-Sci  |i 6113272 
927 |t Library of Congress classification  |a QR189 .N489 1997  |l JCL  |c JCL-Sci  |e CRERAR  |b 47919268  |i 5180004 
The John Crerar Library bookplate

Similar Items